Novartis Raises Full-Year Earnings Guidance Despite Trial Setbacks
Novartis cited solid sales growth and productivity gains as it raised full-year earnings guidance. Clinical-trial setbacks weighed on third-quarter profit.
By Adria CalatayudNovartis raised its full-year earnings guidance, citing solid sales growth and productivity gains, even as recent clinical-trial setbacks hit the Swiss drugmaker's bottom line in the third quarter.The company has been grappling with declining revenue from aging medicines that used…